23andMe for Healthcare Professionals

Advancing patient health. Together.

23andMe has more than 15 million customers worldwide. Our Health + Ancestry and Membership services allows individuals to acquire this information from the privacy of their own homes, without medical requisition.

Nearly 30% of consumers who undergo direct-to-consumer (DTC) genetic testing choose to share their reports with healthcare providers to inform conversations about their health.1,2,3 Our Healthcare Professionals community was created to help U.S. providers and their patients navigate genetics together in order to make important informed decisions about prevention, treatment and healthy living.

Join our community to receive important updates about new features and information about upcoming educational programs and engagement opportunities.

The 23andMe Medical Professionals site is not intended for individuals in the EU.

Helping people access, understand and benefit from the human genome.

 

At 23andMe, we believe that when consumers engage with their genetics, they are able to play a more active role in their health. We also believe the human genome holds the promise of contributing to major breakthroughs in medical research efforts. We go beyond genetic testing to engage consumers in research with the goal of accelerating therapeutic development. ~80% of our customers consent to participate in research, making 23andMe an important study partner in pioneering research.

Direct-to-consumer genetics

The 23andMe Personal Genetic Service provides information and tools for individuals to learn about their DNA.

Research
services

23andMe researchers and our collaborators make meaningful discoveries using genetic data and survey information.

Drug
discovery

23andMe Therapeutics strives to use human genetic data to accelerate the discovery of novel treatments.

Health Predispositions*

10+ reports

  • Genetic Health Risks
    (Meets FDA Requirements):
  • 10+ reports including:
  • BRCA1/BRCA2 (Selected Variants)
  • Heart Health Familial Hypercholesterolemia
  • Late-Onset Alzheimer's Disease
  • Parkinson's Disease
    • Powered by 23andMe Research
  • 30+ reports including:
  • Heart Health Atrial Fibrillation
  • Heart Health Coronary Artery Disease
  • Heart Health High Blood Pressure
  • Heart Health LDL Cholesterol
  • Migraine
  • Obstructive Sleep Apnea
  • Heart Health Type 2 Diabetes
  • Uterine Fibroids

Pharmacogenetics*

5+ reports

  • (Meets FDA Requirements):
  • 5+ reports including:
  • CYP2C19 Drug Metabolism
  • DPYD Drug Metabolism
  • SLCO1B1 Drug Transport
  • Related Medication Insights

Carrier Status*

45+ reports

  • (Meets FDA Requirements):
  • 45+ reports including:
  • Cystic Fibrosis
  • Sickle Cell Anemia
  • Hereditary Hearing Loss

Ancestry Service Reports

50+ reports

  • 50+ reports including:
  • Ancestry Composition
  • Maternal & Paternal Haplogroups
  • Neanderthal Ancestry

Wellness

5+ reports

  • 5+ reports including:
  • Deep Sleep
  • Lactose Intolerance
  • Genetic Weight
  • sample report

Traits

30+ reports

  • 30+ reports including:
  • Hair Loss
  • Sweet vs. Salty
  • Unibrow
  • sample report

Engaging reports, expanding knowledge.

The first and only DTC genetic test that includes FDA-authorized Genetic Health Risk, Cancer Predisposition, Carrier Status, and Pharmacogenetics reports.

 

What causes consumers to pursue DTC genetic testing? Motivations include obtaining health-related information, learning about genetic risk factors, curiosity in genetics, contributing to research and investigating self-identity.4

For individuals interested in genetic health information, it’s important to note that the 23andMe experience is not intended to be a diagnostic tool. Our objective is not to detect disease, but to deliver genetic information in the most engaging and responsible way. Our Health Predisposition (including Genetic Health Risk), Pharmacogenetics, and Carrier Status reports* may, in certain cases, provide valuable information for clinical management.

Explore our reports to better understand the types of information your patients receive and may share with you.

Meet the Team

FAQ

Questions? Contact us at medical@23andme.com.

* The 23andMe PGS test includes health predisposition and carrier status reports. Health predisposition reports include both reports that meet FDA requirements for genetic health risks and reports which are based on 23andMe research and have not been reviewed by the FDA. The test uses qualitative genotyping to detect select clinically relevant variants in the genomic DNA of adults from saliva for the purpose of reporting and interpreting genetic health risks and reporting carrier status. It is not intended to diagnose any disease. Your ethnicity may affect the relevance of each report and how your genetic health risk results are interpreted. Each genetic health risk report describes if a person has variants associated with a higher risk of developing a disease, but does not describe a person's overall risk of developing the disease. The test is not intended to tell you anything about your current state of health, or to be used to make medical decisions, including whether or not you should take a medication, how much of a medication you should take, or determine any treatment. Our carrier status reports can be used to determine carrier status, but cannot determine if you have two copies of any genetic variant. These carrier reports are not intended to tell you anything about your risk for developing a disease in the future, the health of your fetus, or your newborn child's risk of developing a particular disease later in life. For certain conditions, we provide a single report that includes information on both carrier status and genetic health risk. Warnings & Limitations: The 23andMe PGS Genetic Health Risk Report for BRCA1/BRCA2 (Selected Variants) is indicated for reporting of 44 variants in the BRCA1 and BRCA2 genes. The report describes if a person's genetic result is associated with an increased risk of developing breast cancer and ovarian cancer and may be associated with an increased risk for prostate cancer, pancreatic cancer, and potentially other cancers. The variants included in this report do not represent the majority of the BRCA1/BRCA2 variants in people of most ethnicities. This report does not include variants in other genes linked to hereditary cancers and the absence of variants included in this report does not rule out the presence of other genetic variants that may impact cancer risk. This report is for over-the-counter use by adults over the age of 18, and provides genetic information to inform discussions with a healthcare professional. The PGS test is not a substitute for visits to a healthcare professional for recommended screenings or appropriate follow-up. Results should be confirmed in a clinical setting before taking any medical action. For important information and limitations regarding each genetic health risk and carrier status report, visit 23andme.com/test-info/

**23andMe PGS Pharmacogenetics reports: The 23andMe test uses qualitative genotyping to detect 3 variants in the CYP2C19 gene, 2 variants in the DPYD gene and 1 variant in the SLCO1B1 gene in the genomic DNA of adults from saliva for the purpose of reporting and interpreting information about the processing of certain therapeutics to inform discussions with a healthcare professional. It does not describe if a person will or will not respond to a particular therapeutic. Our CYP2C19 Pharmacogenetics report provides certain information about variants associated with metabolism of some therapeutics and provides interpretive drug information regarding the potential effect of citalopram and clopidogrel therapy. Our SLCO1B1 Pharmacogenetics report provides certain information about variants associated with the processing of some therapeutics and provides interpretive drug information regarding the potential effect of simvastatin therapy. Our DPYD Pharmacogenetics report does not describe the association between detected variants and any specific therapeutic. Results for DPYD and certain CYP2C19 results should be confirmed by an independent genetic test prescribed by your own healthcare provider before taking any medical action. Warning: Test information should not be used to start, stop, or change any course of treatment and does not test for all possible variants that may affect metabolism or protein function. The PGS test is not a substitute for visits to a healthcare professional. Making changes to your current regimen can lead to harmful side effects or reduced intended benefits of your medication, therefore consult with your healthcare professional before taking any medical action. For important information and limitations regarding Pharmacogenetic reports, visit 23andme.com/test-info/pharmacogenetics/